Wanbury Limited (WANBURY) AI Stock Analysis

• Market Cap: ₹7.82B
• Dividend Yield: N/A
• Average Volume (3M): 8.26K
• Price to Earnings (P/E): 15.1
• Beta (1Y): 2.13
• Revenue Growth: 8.92%
• EPS Growth: -5.56%
• Country: IN
• Employees: 1,491
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 4.62
• Shares Outstanding: 32,877,000
• 10 Day Avg. Volume: 8,584
• 30 Day Avg. Volume: 8,255
• PEG Ratio: -0.63
• Price to Book (P/B): 14.81
• Price to Sales (P/S): 1.46
• P/FCF Ratio: -38.28
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: ₹270.00 ▲(17.29% Upside)

Wanbury Limited's overall stock score reflects strong financial performance driven by revenue growth and improving margins, offset by high leverage and liquidity challenges. Technical indicators suggest a neutral trend, while valuation metrics indicate reasonable pricing.

Positive Factors

Revenue Growth

Consistent revenue growth indicates expanding market reach and product adoption, which can enhance long-term financial stability and competitiveness.

Profitability Margins

Improving profitability margins suggest enhanced operational efficiency, which can lead to better financial health and competitive positioning over time.

Cash Management

Improved operating cash flow indicates efficient cash management, supporting the company's ability to invest in growth and manage debts effectively.

Negative Factors

High Leverage

High leverage can strain financial resources and limit flexibility, posing risks to long-term stability and increasing vulnerability to economic downturns.

Negative Free Cash Flow

Negative free cash flow highlights potential liquidity challenges, which can hinder the company's ability to fund operations and growth initiatives sustainably.

Fluctuating Net Profit Margin

Fluctuating net profit margins indicate instability in profitability, which can affect long-term financial planning and investor confidence.

Wanbury Limited Business Overview & Revenue Model

Company Description

Wanbury Limited (WANBURY) is a pharmaceutical company based in India that specializes in the development, manufacturing, and marketing of a diverse range of generic and specialty medicines. The company operates primarily in the healthcare sector, focusing on therapeutic areas such as cardiology, psychiatry, neurology, and gynecology. Wanbury is known for its commitment to quality and innovation, with a portfolio that includes both oral and injectable formulations, catering to the needs of various markets across India and internationally.

How the Company Makes Money

Wanbury generates revenue primarily through the sale of pharmaceutical products, including generics and specialty drugs, to healthcare providers, pharmacies, and distributors. The company has established key revenue streams through its extensive product portfolio and a strong distribution network that allows it to reach a wide customer base. Additionally, Wanbury's revenue is bolstered by strategic partnerships and collaborations with other pharmaceutical firms, which can include joint ventures for research and development, as well as licensing agreements that expand its market reach and product offerings. The company also benefits from export sales, as it supplies its products to international markets, thereby diversifying its income sources and enhancing its overall financial performance.

Wanbury Limited Financial Statement Overview

Summary

Wanbury Limited shows strong revenue growth and improving profitability margins, but faces challenges with high leverage and consistent free cash flow deficits. Continued focus on debt management and cash flow enhancement is crucial for sustained financial stability.

Income Statement

Wanbury Limited shows a strong recovery in revenue with a noticeable growth rate from 2023 to 2025. The gross profit and EBIT margins have improved, indicating enhanced operational efficiency. However, net profit margin is fluctuating, showing some instability in profitability. Despite this, the overall trend appears positive with EBITDA margins also showing strength.

Balance Sheet

The company's debt-to-equity ratio indicates high leverage which poses a potential risk, but the positive stockholders' equity in 2025 is a significant improvement from previous negative values. The equity ratio is low, indicating a higher reliance on debt, but the return on equity is improving, suggesting better profitability management.

Cash Flow

Operating cash flow has shown improvement with positive trends, though free cash flow remains negative in recent years, highlighting potential liquidity challenges. The operating cash flow to net income ratio is strong, indicating efficient cash management relative to earnings.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.30B	6.00B	5.74B	4.98B	5.11B	3.87B
Gross Profit	3.26B	3.05B	2.65B	1.89B	2.04B	1.61B
EBITDA	926.84M	798.13M	985.49M	234.91M	1.13B	204.23M
Net Income	429.83M	305.30M	559.56M	-103.96M	814.74M	-126.06M
Balance Sheet
Total Assets	0.00	4.14B	3.43B	3.04B	3.53B	2.89B
Cash, Cash Equivalents and Short-Term Investments	129.60M	150.63M	34.00M	14.94M	226.56M	101.31M
Total Debt	0.00	1.77B	1.16B	1.09B	1.08B	2.04B
Total Liabilities	-592.72M	3.55B	3.16B	3.36B	3.76B	4.45B
Stockholders Equity	592.72M	592.72M	279.41M	-61.54M	-234.20M	-1.56B
Cash Flow
Free Cash Flow	0.00	-229.26M	-134.45M	71.69M	308.65M	122.53M
Operating Cash Flow	0.00	261.02M	39.78M	197.97M	405.23M	166.81M
Investing Cash Flow	0.00	-511.74M	-166.25M	-88.38M	5.87M	80.44M
Financing Cash Flow	0.00	257.33M	145.53M	-319.91M	-285.85M	-173.85M

Wanbury Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 230.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:WANBURY, the sentiment is Negative. The current price of 230.2 is below the 20-day moving average (MA) of 239.19, below the 50-day MA of 243.26, and below the 200-day MA of 256.13, indicating a bearish trend. The MACD of -2.74 indicates Positive momentum. The RSI at 41.49 is Neutral, neither overbought nor oversold. The STOCH value of 29.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:WANBURY.

Wanbury Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SAKAR	66 Neutral	₹9.11B	47.51	―	―	24.20%	55.01%
WANBURY	64 Neutral	₹7.82B	15.07	―	―	8.92%	-5.56%
KILITCH	57 Neutral	₹5.89B	19.80	―	―	32.95%	67.39%
KOPRAN	57 Neutral	₹6.29B	35.69	―	2.32%	-6.96%	-66.75%
THEMISMED	54 Neutral	₹9.45B	-34.56	―	0.50%	-18.86%	-150.92%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Wanbury Limited Corporate Events

Wanbury Limited Allots Shares Under ESOP

Wanbury Limited announced the allotment of 15,000 equity shares to an eligible employee under its Employee Stock Option Plan 2016. This move, approved during the board meeting on November 13, 2025, will increase the company’s paid-up share capital slightly, reflecting a commitment to employee incentives and potentially impacting shareholder value.

Wanbury Limited Allots Rs. 25 Crore Debentures to Tata Capital

Wanbury Limited’s Day-to-Day Affairs Committee of the Board of Directors approved the allotment of 250 Unlisted, Secured Redeemable, Non-Convertible Debentures to Tata Capital Limited, amounting to Rs. 25 Crores. This move aims to finance the company’s capital expenditure and working capital requirements, as well as address identified liabilities, potentially strengthening its financial position and operational capabilities.